A protocol for handling the assertion of attorney-client privilege and the attorney work-product claims has been set in litigation in which plaintiffs allege they developed pancreatic cancer from taking one of four incretin-based drugs.
According to the order from U.S. District Judge Anthony Battaglia of the Southern District of California, the parties were unable to agree on the source of law for disputes regarding whether attorney-client privilege shields some evidence. But the parties did agree that federal law would govern discovery disputes involving the attorney work-product doctrine.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
